Latest Breaking News On - Ulrike gnad vogt - Page 10 : comparemela.com

Press release content from Accesswire. The AP news staff was not involved in its creation. CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma February 4, 2021 GMT Trial expansion focuses on advanced melanoma, an indication of high medical need TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 4, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the start of an expansion of the ongoing Phase 1 study with its lead RNA-based cancer drug candidate, CV8102. Initial results from the dose-escalation part in four solid cancer types were presented at the SITC conference in 2020. CV8102 had shown promising evidence of efficacy after intratumoral application as a single agent, and in combination with systemic anti-PD-1 antibody treatment. Translation of a locally induced immune response into a systemic immune response was observed

United statesUlrike gnad vogtSarah fakihExchange commissionSenior vice president area head oncologyNew york nasdaqVice presidentVice president investorஒன்றுபட்டது மாநிலங்களில்சாரா ஃபேகிபரிமாற்றம் தரகுமூத்தவர் துணை ப்ரெஸிடெஂட் பரப்பளவு தலை புற்றுநோயியல்புதியது யார்க் நாஸ்டாக்துணை ப்ரெஸிடெஂட்துணை ப்ரெஸிடெஂட் முதலீட்டாளர்